The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, an...
Inhibidores de las Cinasas Janus/uso terapéutico,
COVID-19/tratamiento farmacológico,
Antivirales/uso terapéutico,
Ivermectina/uso terapéutico,
Hidroxicloroquina/uso terapéutico,
Plasma/inmunología,
Fluvoxamina/uso terapéutico,
Colchicina/uso terapéutico,
Inmunización Pasiva,
Receptores de Interleucina-6/uso terapéutico,
Lopinavir/uso terapéutico,
Corticoesteroides/uso terapéutico
The WHO COVID-19 Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is impor...
COVID-19/complicaciones,
COVID-19/diagnóstico,
Máscaras,
Salud Global,
Hospitalización,
Respiración Artificial,
Choque Séptico,
Lactancia Materna,
Embarazo,
Síndrome de Dificultad Respiratoria/etiología,
Neumonía Viral/etiología,
Cuidados Paliativos,
Rehabilitación,
Manejo de Atención al Paciente/organización & administración
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing...
As the HIV response moves to focusing on closing the remaining gaps in prevention, testing and treatment services, an evolution in the underlying routine data systems is needed to identify epidemiologic patterns and service gaps, and accelerate focused interventions.
These guidelines focus on the collec...
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released in 2018 ...
